Emergent BioSolutions (EBS) Tops Q3 EPS by $1.27
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.14 --0%
Revenue Growth %: +32.0%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +32.0%
Financial Fact:
Research and development: 27.19M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.37, $1.27 better than the analyst estimate of $0.10. Revenue for the quarter came in at $293.8 million versus the consensus estimate of $290.33 million.
GUIDANCE:
Emergent BioSolutions sees FY2024 revenue of $1.065-1.125 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Upgrades Five Below (FIVE) to Outperform, 'we believe the pendulum has swung too far on valuation'
- Goldman Sachs: We see modest upside for IBM, tactical idea for Q2
- Levi (LEVI) Tops Q2 EPS by 4c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
